

Resource Summary Report

Generated by NIF on Sep 8, 2026

APC anti-mouse Ly-6G

RRID:AB_1877163

Type: Antibody

Proper Citation

BioLegend Cat# 127613, RRID:AB_1877163

Antibody Information

URL: http://antibodyregistry.org/AB_1877163

Proper Citation: BioLegend Cat# 127613, RRID:AB_1877163

Target Antigen: Ly-6G

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse Ly-6G

Description: This monoclonal targets Ly-6G

Target Organism: mouse

Clone ID: Clone 1A8

Antibody ID: AB_1877163

Vendor: BioLegend

Catalog Number: 127613

Alternative Catalog Numbers: 127614

Record Creation Time: 20231110T051541+0000

Record Last Update: 20260829T093949+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse Ly-6G.

No alerts have been found for APC anti-mouse Ly-6G.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 66 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yu Y, et al. (2026) A stress-responsive neurovascular axis shapes skin immune accessibility. *iScience*, 29(3), 115122.

Shah DC, et al. (2026) Exogenous sphingomyelinase mediates MSC-derived EV biogenesis and enhances potency via repackaging of molecular cargo. *iScience*, 29(3), 114992.

Zhang X, et al. (2026) *Lactobacillus delbrueckii* surface protein P4430 attenuates intestinal inflammation by modulating macrophage polarization via Mincle. *Cell reports*, 45(2), 116869.

Tam HT, et al. (2026) Hyperinnervation inhibits organ-level regeneration in mammalian skin. *Cell*, 189(11), 3270.

Lu L, et al. (2026) Enalaprilat reverses neutrophil polarization imbalance via targeting taurine-STING axis for treatment of diabetic wounds. *Cell reports. Medicine*, 7(4), 102714.

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. *Cancer immunology research*, 14(1), 90.

Wu HL, et al. (2025) DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer. *Med (New York, N.Y.)*, 6(3), 100535.

Luan Y, et al. (2025) IgG2c subclass dominance drives fatal lupus-like nephritis via FcγR and complement activation. *Cell reports*, 45(1), 116775.

Hsu AY, et al. (2025) Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution. *Cell*, 188(6), 1623.

Li L, et al. (2025) β2 integrin regulates neutrophil trans endothelial migration following traumatic brain injury. *Cell communication and signaling : CCS*, 23(1), 70.

Xu B, et al. (2025) Fatty acids modulate the colorectal cancer immune microenvironment via regulating the interaction and transactivation of PPARα and P53. *Cell reports*, 44(12), 116623.

Tang Q, et al. (2025) Gut bacterial L-lysine alters metabolism and histone methylation to drive dendritic cell tolerance. *Cell reports*, 44(1), 115125.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8⁺ effector T cell function and immunotherapy efficacy. *Cell reports. Medicine*, 6(9), 102324.

Yamada-Hara M, et al. (2025) ROR γ t Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer. *Cancer immunology research*, 13(9), 1418.

Vigo T, et al. (2025) Noradrenergic control of bone marrow and thymus by AgRP neurons is impaired in experimental multiple sclerosis. *Cell reports*, 44(11), 116556.

Wen H, et al. (2025) NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment. *iScience*, 28(10), 113519.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.